Chipscreen(SH:688321) Zheng Quan Ri Bao Wang·2025-10-31 03:39Core Insights - Shenzhen MicuRx Biotech Co., Ltd. reported a significant revenue growth of 40.12% year-on-year, reaching 674 million yuan in the first three quarters of 2025, with Q3 revenue at 268 million yuan, marking a 49.51% increase [1] - The net profit attributable to shareholders for Q3 was 41.1753 million yuan, while the net profit for the first three quarters was 70.7675 million yuan [1] - The growth in performance is primarily driven by increased sales of the products Sidabenan and Siglecatin, with Sidabenan sales up 18.76% and Siglecatin sales soaring by 136.13% year-on-year [1] Company Strategy - MicuRx is leveraging a global development strategy based on early research in China, assembling a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that utilizes AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - MicuRx has successfully developed first-in-class and best-in-class innovative drugs, with two innovative drugs already marketed globally across multiple indications [1] Product Portfolio - The company has established a diverse pipeline of research projects with differentiated advantages and global competitiveness in five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]